Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferretab is an oral iron supplement formulation developed and manufactured by G.L. Pharma. It primarily consists of ferrous (II) fumarate, a stable iron salt, combined with ascorbic acid (Vitamin C) to enhance intestinal iron absorption. A variant known as Ferretab comp. includes folic acid instead of ascorbic acid. The drug is delivered in a prolonged-release capsule format, providing 50 mg of elemental iron per dose. It is indicated for the treatment and prevention of iron deficiency and iron deficiency anemia, particularly in pregnant women and those undergoing fertility treatments. By replenishing iron stores, Ferretab stimulates hemoglobin synthesis and red blood cell production. It has been evaluated in Phase 4 clinical trials, such as those conducted by Das Kinderwunsch Institut Schenk, to compare its efficacy with intravenous iron therapies in women undergoing ovarian stimulation and other fertility procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous fumarate + ascorbic acid (G.L. Pharma).